Loading…
Reported covered position: Legislative Correspondent; Legislative Assistant; Legislative Director; Senior Health Policy Advisor; Deputy Legislative Director
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
H.R. 4101 - Cancer Drug Parity Act of 2025 H.R. 5178 - Sickle Cell Disease Comprehensive Care Act S. 3510 - Biosimilar Inspection Modernization Act of 2025 Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Codification FDA-2026-N-4699 - Expedited Investigational New Drug (IND) pilot program Section 301 Investigation re: Germany Issues FDA User Fee Agreements: 2027 PDUFA Cycle 340B Program Reform Prior Authorization Vaccine Access and Coverage FDA Modernization and Reforms Drug Pricing PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage Pandemic and All-Hazards Preparedness Act (PAHPA)
Protecting Patient Access to Cancer and Complex Therapies Act
Client: PFIZER INC. · Firm: PFIZER INC.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
2026 · third_quarter · Q3
H.R. 5256 - 340B ACCESS Act H.R. 9599 - SECURE 340B Act Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Vaccine Access and Coverage 340B Program Reform Hospital Outpatient Prospective Payment System (OPPS) Proposed Rule/Essential Medicines PBM Reform Drug Pricing Medicare/Medicaid Issues
H.R. 4101 - Cancer Drug Parity Act of 2025 H.R. 5178 - Sickle Cell Disease Comprehensive Care Act S. 3510 - Biosimilar Inspection Modernization Act of 2025 Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Codification FDA-2026-N-4699 - Expedited Investigational New Drug (IND) pilot program Section 301 Investigation re: Germany Issues FDA User Fee Agreements: 2027 PDUFA Cycle 340B Program Reform Prior Authorization Vaccine Access and Coverage FDA Modernization and Reforms Drug Pricing PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage Pandemic and All-Hazards Preparedness Act (PAHPA)
Source: Senate LDA
Vaccine Coverage and Coverage Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Codification and Sec. 301 trade investigations FDA User Fee Agreements: 2027 PDUFA Cycle H.R. 7837 - Most Favored Patient Act of 2026 H.R. 7391 - Community Health Center Drug Pricing Protection Act 340B Program Reform Inflation Reduction Act (IRA) H.R. 8646 - Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriates Act, 2027 H.R. 9260 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriation Act, 2027 H.R. 5178 - Sickle Cell Disease Comprehensive Care Act H.R. 5526 - Biosimilars Red Tape Elimination Act H.R. 4930 - To Expand the Sharing of Information with Respect to Suspected Violations of Intellectual Property Rights in Trade H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act: IRA reforms Prior Authorization Step Therapy Practices FDA Modernization and Reforms Drug Pricing PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage
To expand the sharing of information with respect to suspected violations of intellectual property rights in trade.
Client: PFIZER INC. · Firm: PFIZER INC.
H.R. 9102 - Biotech Investment National Security Act (BINSA) Act: US Competitiveness, Biotechnology H.R. 4930 - To Expand the Sharing of Information with Respect to Suspected Violations of Intellectual Property Rights in Trade International Supply Chain Section 301 Investigation re: Germany Issues Market Access Most Favored Nation Policies Foreign Freeriding Issues Non-Tariff Trade Barriers Competitiveness Issues Trade Issues
To expand the sharing of information with respect to suspected violations of intellectual property rights in trade.
Client: PFIZER INC. · Firm: PFIZER INC.
Vaccine Coverage and Coverage Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Codification and Sec. 301 trade investigations FDA User Fee Agreements: 2027 PDUFA Cycle H.R. 7837 - Most Favored Patient Act of 2026 H.R. 7391 - Community Health Center Drug Pricing Protection Act 340B Program Reform Inflation Reduction Act (IRA) H.R. 8646 - Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriates Act, 2027 H.R. 9260 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriation Act, 2027 H.R. 5178 - Sickle Cell Disease Comprehensive Care Act H.R. 5526 - Biosimilars Red Tape Elimination Act H.R. 4930 - To Expand the Sharing of Information with Respect to Suspected Violations of Intellectual Property Rights in Trade H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act: IRA reforms Prior Authorization Step Therapy Practices FDA Modernization and Reforms Drug Pricing PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage
Vaccine Coverage and Coverage Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Codification and Sec. 301 trade investigations FDA User Fee Agreements: 2027 PDUFA Cycle H.R. 7837 - Most Favored Patient Act of 2026 H.R. 7391 - Community Health Center Drug Pricing Protection Act 340B Program Reform Inflation Reduction Act (IRA) H.R. 8646 - Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriates Act, 2027 H.R. 9260 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriation Act, 2027 H.R. 5178 - Sickle Cell Disease Comprehensive Care Act H.R. 5526 - Biosimilars Red Tape Elimination Act H.R. 4930 - To Expand the Sharing of Information with Respect to Suspected Violations of Intellectual Property Rights in Trade H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act: IRA reforms Prior Authorization Step Therapy Practices FDA Modernization and Reforms Drug Pricing PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage
H.R. 4101 - Cancer Drug Parity Act of 2025 H.R. 5178 - Sickle Cell Disease Comprehensive Care Act S. 3510 - Biosimilar Inspection Modernization Act of 2025 Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Codification FDA-2026-N-4699 - Expedited Investigational New Drug (IND) pilot program Section 301 Investigation re: Germany Issues FDA User Fee Agreements: 2027 PDUFA Cycle 340B Program Reform Prior Authorization Vaccine Access and Coverage FDA Modernization and Reforms Drug Pricing PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage Pandemic and All-Hazards Preparedness Act (PAHPA)
H.R. 5256 - 340B ACCESS Act H.R. 9599 - SECURE 340B Act Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Vaccine Access and Coverage 340B Program Reform Hospital Outpatient Prospective Payment System (OPPS) Proposed Rule/Essential Medicines PBM Reform Drug Pricing Medicare/Medicaid Issues
Vaccine Coverage Pediatric Immunization Schedule Vaccine Injury Compensation Program Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 7837 - Most Favored Patient Act of 2026 Lyme Disease Issues 340B Issues Counterfeit Drugs Inflation Reduction Act (IRA) Prescription Drug User Fee Act (PDUFA) Drug Pricing PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 3510 - Biosimilar Inspection Modernization Act of 2025
Vaccine Coverage Pediatric Immunization Schedule Vaccine Injury Compensation Program Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 7837 - Most Favored Patient Act of 2026 Lyme Disease Issues 340B Issues Counterfeit Drugs Inflation Reduction Act (IRA) Prescription Drug User Fee Act (PDUFA) Drug Pricing PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 3510 - Biosimilar Inspection Modernization Act of 2025
Vaccine Coverage and Coverage Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Codification and Sec. 301 trade investigations FDA User Fee Agreements: 2027 PDUFA Cycle H.R. 7837 - Most Favored Patient Act of 2026 H.R. 7391 - Community Health Center Drug Pricing Protection Act 340B Program Reform Inflation Reduction Act (IRA) H.R. 8646 - Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriates Act, 2027 H.R. 9260 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriation Act, 2027 H.R. 5178 - Sickle Cell Disease Comprehensive Care Act H.R. 5526 - Biosimilars Red Tape Elimination Act H.R. 4930 - To Expand the Sharing of Information with Respect to Suspected Violations of Intellectual Property Rights in Trade H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act: IRA reforms Prior Authorization Step Therapy Practices FDA Modernization and Reforms Drug Pricing PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage
Vaccine Coverage and Coverage Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Codification and Sec. 301 trade investigations FDA User Fee Agreements: 2027 PDUFA Cycle H.R. 7837 - Most Favored Patient Act of 2026 H.R. 7391 - Community Health Center Drug Pricing Protection Act 340B Program Reform Inflation Reduction Act (IRA) H.R. 8646 - Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriates Act, 2027 H.R. 9260 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriation Act, 2027 H.R. 5178 - Sickle Cell Disease Comprehensive Care Act H.R. 5526 - Biosimilars Red Tape Elimination Act H.R. 4930 - To Expand the Sharing of Information with Respect to Suspected Violations of Intellectual Property Rights in Trade H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act: IRA reforms Prior Authorization Step Therapy Practices FDA Modernization and Reforms Drug Pricing PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage
H.R. 7391 - Community Health Center Drug Pricing Protection Act Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Vaccine Access and Coverage 340B Program Reform PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage Step Therapy Practices Drug Pricing Medicare/Medicaid Issues
Vaccine Coverage Pediatric Immunization Schedule Vaccine Injury Compensation Program Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 7837 - Most Favored Patient Act of 2026 Lyme Disease Issues 340B Issues Counterfeit Drugs Inflation Reduction Act (IRA) Prescription Drug User Fee Act (PDUFA) Drug Pricing PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 3510 - Biosimilar Inspection Modernization Act of 2025
Vaccine Coverage and Coverage Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Codification and Sec. 301 trade investigations FDA User Fee Agreements: 2027 PDUFA Cycle H.R. 7837 - Most Favored Patient Act of 2026 H.R. 7391 - Community Health Center Drug Pricing Protection Act 340B Program Reform Inflation Reduction Act (IRA) H.R. 8646 - Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriates Act, 2027 H.R. 9260 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriation Act, 2027 H.R. 5178 - Sickle Cell Disease Comprehensive Care Act H.R. 5526 - Biosimilars Red Tape Elimination Act H.R. 4930 - To Expand the Sharing of Information with Respect to Suspected Violations of Intellectual Property Rights in Trade H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act: IRA reforms Prior Authorization Step Therapy Practices FDA Modernization and Reforms Drug Pricing PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage
Vaccine Coverage Pediatric Immunization Schedule Vaccine Injury Compensation Program Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 7837 - Most Favored Patient Act of 2026 Lyme Disease Issues 340B Issues Counterfeit Drugs Inflation Reduction Act (IRA) Prescription Drug User Fee Act (PDUFA) Drug Pricing PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 3510 - Biosimilar Inspection Modernization Act of 2025
Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027
Client: PFIZER INC. · Firm: PFIZER INC.
Vaccine Coverage and Coverage Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Codification and Sec. 301 trade investigations FDA User Fee Agreements: 2027 PDUFA Cycle H.R. 7837 - Most Favored Patient Act of 2026 H.R. 7391 - Community Health Center Drug Pricing Protection Act 340B Program Reform Inflation Reduction Act (IRA) H.R. 8646 - Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriates Act, 2027 H.R. 9260 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriation Act, 2027 H.R. 5178 - Sickle Cell Disease Comprehensive Care Act H.R. 5526 - Biosimilars Red Tape Elimination Act H.R. 4930 - To Expand the Sharing of Information with Respect to Suspected Violations of Intellectual Property Rights in Trade H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act: IRA reforms Prior Authorization Step Therapy Practices FDA Modernization and Reforms Drug Pricing PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage
H.R. 9102 - Biotech Investment National Security Act (BINSA) Act: US Competitiveness, Biotechnology Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients FDA-2026-N-4699 - Expedited Investigational New Drug (IND) pilot program International Supply Chain Section 301 Investigation re: Germany Issues Foreign Freeriding Issues Non-Tariff Trade Barriers Global Health Competitiveness Issues Clinical Trial Issues
H.R. 9102 - Biotech Investment National Security Act (BINSA) Act: US Competitiveness, Biotechnology H.R. 4930 - To Expand the Sharing of Information with Respect to Suspected Violations of Intellectual Property Rights in Trade International Supply Chain Section 301 Investigation re: Germany Issues Market Access Most Favored Nation Policies Foreign Freeriding Issues Non-Tariff Trade Barriers Competitiveness Issues Trade Issues
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027
Client: PFIZER INC. · Firm: PFIZER INC.
Vaccine Coverage and Coverage Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Codification and Sec. 301 trade investigations FDA User Fee Agreements: 2027 PDUFA Cycle H.R. 7837 - Most Favored Patient Act of 2026 H.R. 7391 - Community Health Center Drug Pricing Protection Act 340B Program Reform Inflation Reduction Act (IRA) H.R. 8646 - Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriates Act, 2027 H.R. 9260 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriation Act, 2027 H.R. 5178 - Sickle Cell Disease Comprehensive Care Act H.R. 5526 - Biosimilars Red Tape Elimination Act H.R. 4930 - To Expand the Sharing of Information with Respect to Suspected Violations of Intellectual Property Rights in Trade H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act: IRA reforms Prior Authorization Step Therapy Practices FDA Modernization and Reforms Drug Pricing PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage
H.R. 5256 - 340B ACCESS Act H.R. 9599 - SECURE 340B Act Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Vaccine Access and Coverage 340B Program Reform Hospital Outpatient Prospective Payment System (OPPS) Proposed Rule/Essential Medicines PBM Reform Drug Pricing Medicare/Medicaid Issues
Vaccine Coverage Pediatric Immunization Schedule Vaccine Injury Compensation Program Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 7837 - Most Favored Patient Act of 2026 Lyme Disease Issues 340B Issues Counterfeit Drugs Inflation Reduction Act (IRA) Prescription Drug User Fee Act (PDUFA) Drug Pricing PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 3510 - Biosimilar Inspection Modernization Act of 2025
Vaccine Coverage Pediatric Immunization Schedule Vaccine Injury Compensation Program Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 7837 - Most Favored Patient Act of 2026 Lyme Disease Issues 340B Issues Counterfeit Drugs Inflation Reduction Act (IRA) Prescription Drug User Fee Act (PDUFA) Drug Pricing PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 3510 - Biosimilar Inspection Modernization Act of 2025
Vaccine Coverage Pediatric Immunization Schedule Vaccine Injury Compensation Program Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 7837 - Most Favored Patient Act of 2026 Lyme Disease Issues 340B Issues Counterfeit Drugs Inflation Reduction Act (IRA) Prescription Drug User Fee Act (PDUFA) Drug Pricing PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 3510 - Biosimilar Inspection Modernization Act of 2025
Vaccine Coverage Pediatric Immunization Schedule Vaccine Injury Compensation Program Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 7837 - Most Favored Patient Act of 2026 Lyme Disease Issues 340B Issues Counterfeit Drugs Inflation Reduction Act (IRA) Prescription Drug User Fee Act (PDUFA) Drug Pricing PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 3510 - Biosimilar Inspection Modernization Act of 2025
H.R. 4101 - Cancer Drug Parity Act of 2025 H.R. 5178 - Sickle Cell Disease Comprehensive Care Act S. 3510 - Biosimilar Inspection Modernization Act of 2025 Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Codification FDA-2026-N-4699 - Expedited Investigational New Drug (IND) pilot program Section 301 Investigation re: Germany Issues FDA User Fee Agreements: 2027 PDUFA Cycle 340B Program Reform Prior Authorization Vaccine Access and Coverage FDA Modernization and Reforms Drug Pricing PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage Pandemic and All-Hazards Preparedness Act (PAHPA)
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: PFIZER INC. · Firm: PFIZER INC.
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of 2025 HR 1 - One Big Beautiful Bill Act CDC Reform Vaccine Policy Reconciliation Research & Development HR 946 - ORPHAN Cures Act HR 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program HR 2214 - DRUG Act HR 2450 - Prescription Drug Transparency and Affordability Act PL 117-328 Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Biosimilars Access, Reimbursement and Reform 340B Reform Prescription Drug User Fee Act (PDUFA) Inflation Reduction Act (IRA) Pill Penalty Vaccine Coverage and Access Intellectual Property Protections PBM Reform Cancer Policies Drug Pricing
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: PFIZER INC. · Firm: PFIZER INC.
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of 2025 HR 1 - One Big Beautiful Bill Act CDC Reform Vaccine Policy Reconciliation Research & Development HR 946 - ORPHAN Cures Act HR 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program HR 2214 - DRUG Act HR 2450 - Prescription Drug Transparency and Affordability Act PL 117-328 Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Biosimilars Access, Reimbursement and Reform 340B Reform Prescription Drug User Fee Act (PDUFA) Inflation Reduction Act (IRA) Pill Penalty Vaccine Coverage and Access Intellectual Property Protections PBM Reform Cancer Policies Drug Pricing
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: PFIZER INC. · Firm: PFIZER INC.
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of 2025 HR 1 - One Big Beautiful Bill Act CDC Reform Vaccine Policy Reconciliation Research & Development HR 946 - ORPHAN Cures Act HR 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program HR 2214 - DRUG Act HR 2450 - Prescription Drug Transparency and Affordability Act PL 117-328 Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Biosimilars Access, Reimbursement and Reform 340B Reform Prescription Drug User Fee Act (PDUFA) Inflation Reduction Act (IRA) Pill Penalty Vaccine Coverage and Access Intellectual Property Protections PBM Reform Cancer Policies Drug Pricing
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: PFIZER INC. · Firm: PFIZER INC.
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of 2025 HR 1 - One Big Beautiful Bill Act CDC Reform Vaccine Policy Reconciliation Research & Development HR 946 - ORPHAN Cures Act HR 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program HR 2214 - DRUG Act HR 2450 - Prescription Drug Transparency and Affordability Act PL 117-328 Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Biosimilars Access, Reimbursement and Reform 340B Reform Prescription Drug User Fee Act (PDUFA) Inflation Reduction Act (IRA) Pill Penalty Vaccine Coverage and Access Intellectual Property Protections PBM Reform Cancer Policies Drug Pricing
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: PFIZER INC. · Firm: PFIZER INC.
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of 2025 HR 1 - One Big Beautiful Bill Act CDC Reform Vaccine Policy Reconciliation Research & Development HR 946 - ORPHAN Cures Act HR 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program HR 2214 - DRUG Act HR 2450 - Prescription Drug Transparency and Affordability Act PL 117-328 Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Biosimilars Access, Reimbursement and Reform 340B Reform Prescription Drug User Fee Act (PDUFA) Inflation Reduction Act (IRA) Pill Penalty Vaccine Coverage and Access Intellectual Property Protections PBM Reform Cancer Policies Drug Pricing
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: PFIZER INC. · Firm: PFIZER INC.
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 527 - Prescription Pricing for the People Act of 2025 S 832 - EPIC Act of 2025 S 864 - HELP Copays Act S 882 - Patients Before Middlemen Act S 1040 - Drug Competition Enhancement Act HR 946 - ORPHAN Cures Act HR 1492 - EPIC Act Biosimilars Access & Reimbursement 340B Reform 340B Access Act Inflation Reduction Act (IRA) Biosimilar Pause Inflation Reduction Act (IRA) Pill Penalty Vaccine Coverage Intellectual Property Protections PBM Reform Lower Cost More Transparency Act Bayh-Dole Act March-In Rights Cancer Policies Drug Pricing/Foreign Reference Pricing Digital Therapeutics Access & Reimbursement Patient Out of Pocket Costs
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: PFIZER INC. · Firm: PFIZER INC.
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of 2025 HR 1 - One Big Beautiful Bill Act CDC Reform Vaccine Policy Reconciliation Research & Development HR 946 - ORPHAN Cures Act HR 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program HR 2214 - DRUG Act HR 2450 - Prescription Drug Transparency and Affordability Act PL 117-328 Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Biosimilars Access, Reimbursement and Reform 340B Reform Prescription Drug User Fee Act (PDUFA) Inflation Reduction Act (IRA) Pill Penalty Vaccine Coverage and Access Intellectual Property Protections PBM Reform Cancer Policies Drug Pricing
HR 2213 - Authorize the President to Enter Into Trade Agreements for the Reciprocal Elimination of Duties or Other Import Restrictions with Respect to Medical Goods Medical Supply Chain Resiliency Act International Supply Chain Tariffs Non-Tariff Trade Barriers
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of 2025 HR 1 - One Big Beautiful Bill Act CDC Reform Vaccine Policy Reconciliation Research & Development HR 946 - ORPHAN Cures Act HR 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program HR 2214 - DRUG Act HR 2450 - Prescription Drug Transparency and Affordability Act PL 117-328 Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Biosimilars Access, Reimbursement and Reform 340B Reform Prescription Drug User Fee Act (PDUFA) Inflation Reduction Act (IRA) Pill Penalty Vaccine Coverage and Access Intellectual Property Protections PBM Reform Cancer Policies Drug Pricing
Vaccine Policy, Coverage and Access HR 4317 - PMB Reform Act of 2025 Gavi Vaccines Alliance Issues HR 2214 - DRUG Act S 832 - EPIC Act of 2025 S 864 - HELP Copays ACT S 882 - Patients Before Middlemen Act Prescription Drug-Use-Related Software (PDURS): Digital Medicine Lyme Disease Issues Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients IRA Biosimilars Pause Fix, Biosimilar Legislation H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Orphan Drug Exemption, Pill Penalty, Biosimilar Pause Vaccine Coverage and Access Drug Pricing
Vaccine Policy, Coverage and Access HR 4317 - PMB Reform Act of 2025 Gavi Vaccines Alliance Issues HR 2214 - DRUG Act S 832 - EPIC Act of 2025 S 864 - HELP Copays ACT S 882 - Patients Before Middlemen Act Prescription Drug-Use-Related Software (PDURS): Digital Medicine Lyme Disease Issues Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients IRA Biosimilars Pause Fix, Biosimilar Legislation H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Orphan Drug Exemption, Pill Penalty, Biosimilar Pause Vaccine Coverage and Access Drug Pricing
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of 2025 HR 1 - One Big Beautiful Bill Act CDC Reform Vaccine Policy Reconciliation Research & Development HR 946 - ORPHAN Cures Act HR 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program HR 2214 - DRUG Act HR 2450 - Prescription Drug Transparency and Affordability Act PL 117-328 Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Biosimilars Access, Reimbursement and Reform 340B Reform Prescription Drug User Fee Act (PDUFA) Inflation Reduction Act (IRA) Pill Penalty Vaccine Coverage and Access Intellectual Property Protections PBM Reform Cancer Policies Drug Pricing
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of 2025 HR 1 - One Big Beautiful Bill Act CDC Reform Vaccine Policy Reconciliation Research & Development HR 946 - ORPHAN Cures Act HR 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program HR 2214 - DRUG Act HR 2450 - Prescription Drug Transparency and Affordability Act PL 117-328 Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Biosimilars Access, Reimbursement and Reform 340B Reform Prescription Drug User Fee Act (PDUFA) Inflation Reduction Act (IRA) Pill Penalty Vaccine Coverage and Access Intellectual Property Protections PBM Reform Cancer Policies Drug Pricing
Vaccine Policy, Coverage and Access HR 4317 - PMB Reform Act of 2025 Gavi Vaccines Alliance Issues HR 2214 - DRUG Act S 832 - EPIC Act of 2025 S 864 - HELP Copays ACT S 882 - Patients Before Middlemen Act Prescription Drug-Use-Related Software (PDURS): Digital Medicine Lyme Disease Issues Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients IRA Biosimilars Pause Fix, Biosimilar Legislation H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Orphan Drug Exemption, Pill Penalty, Biosimilar Pause Vaccine Coverage and Access Drug Pricing
Prescription Drug Transparency and Affordability Act
Client: PFIZER INC. · Firm: PFIZER INC.
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of 2025 HR 946 - ORPHAN Cures Act HR 2450 - Prescription Drug Transparency and Affordability Act Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients PBM Reform Medicaid Prescription Drug Access Digital Therapeutics
Prescription Drug Transparency and Affordability Act
Client: PFIZER INC. · Firm: PFIZER INC.
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of 2025 HR 1 - One Big Beautiful Bill Act CDC Reform Vaccine Policy Reconciliation Research & Development HR 946 - ORPHAN Cures Act HR 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program HR 2214 - DRUG Act HR 2450 - Prescription Drug Transparency and Affordability Act PL 117-328 Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Biosimilars Access, Reimbursement and Reform 340B Reform Prescription Drug User Fee Act (PDUFA) Inflation Reduction Act (IRA) Pill Penalty Vaccine Coverage and Access Intellectual Property Protections PBM Reform Cancer Policies Drug Pricing
Prescription Drug Transparency and Affordability Act
Client: PFIZER INC. · Firm: PFIZER INC.
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of 2025 HR 946 - ORPHAN Cures Act HR 2450 - Prescription Drug Transparency and Affordability Act Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients PBM Reform Medicaid Prescription Drug Access Digital Therapeutics
Prescription Drug Transparency and Affordability Act
Client: PFIZER INC. · Firm: PFIZER INC.
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of 2025 HR 1 - One Big Beautiful Bill Act CDC Reform Vaccine Policy Reconciliation Research & Development HR 946 - ORPHAN Cures Act HR 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program HR 2214 - DRUG Act HR 2450 - Prescription Drug Transparency and Affordability Act PL 117-328 Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Biosimilars Access, Reimbursement and Reform 340B Reform Prescription Drug User Fee Act (PDUFA) Inflation Reduction Act (IRA) Pill Penalty Vaccine Coverage and Access Intellectual Property Protections PBM Reform Cancer Policies Drug Pricing
Prescription Drug Transparency and Affordability Act
Client: PFIZER INC. · Firm: PFIZER INC.
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of 2025 HR 1 - One Big Beautiful Bill Act CDC Reform Vaccine Policy Reconciliation Research & Development HR 946 - ORPHAN Cures Act HR 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program HR 2214 - DRUG Act HR 2450 - Prescription Drug Transparency and Affordability Act PL 117-328 Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Biosimilars Access, Reimbursement and Reform 340B Reform Prescription Drug User Fee Act (PDUFA) Inflation Reduction Act (IRA) Pill Penalty Vaccine Coverage and Access Intellectual Property Protections PBM Reform Cancer Policies Drug Pricing
Prescription Drug Transparency and Affordability Act
Client: PFIZER INC. · Firm: PFIZER INC.
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of 2025 HR 946 - ORPHAN Cures Act HR 2450 - Prescription Drug Transparency and Affordability Act Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients PBM Reform Medicaid Prescription Drug Access Digital Therapeutics
Vaccine Policy, Coverage and Access HR 4317 - PMB Reform Act of 2025 Gavi Vaccines Alliance Issues HR 2214 - DRUG Act S 832 - EPIC Act of 2025 S 864 - HELP Copays ACT S 882 - Patients Before Middlemen Act Prescription Drug-Use-Related Software (PDURS): Digital Medicine Lyme Disease Issues Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients IRA Biosimilars Pause Fix, Biosimilar Legislation H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Orphan Drug Exemption, Pill Penalty, Biosimilar Pause Vaccine Coverage and Access Drug Pricing
Vaccine Policy, Coverage and Access HR 4317 - PMB Reform Act of 2025 Gavi Vaccines Alliance Issues HR 2214 - DRUG Act S 832 - EPIC Act of 2025 S 864 - HELP Copays ACT S 882 - Patients Before Middlemen Act Prescription Drug-Use-Related Software (PDURS): Digital Medicine Lyme Disease Issues Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients IRA Biosimilars Pause Fix, Biosimilar Legislation H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Orphan Drug Exemption, Pill Penalty, Biosimilar Pause Vaccine Coverage and Access Drug Pricing
Vaccine Policy, Coverage and Access HR 4317 - PMB Reform Act of 2025 Gavi Vaccines Alliance Issues HR 2214 - DRUG Act S 832 - EPIC Act of 2025 S 864 - HELP Copays ACT S 882 - Patients Before Middlemen Act Prescription Drug-Use-Related Software (PDURS): Digital Medicine Lyme Disease Issues Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients IRA Biosimilars Pause Fix, Biosimilar Legislation H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Orphan Drug Exemption, Pill Penalty, Biosimilar Pause Vaccine Coverage and Access Drug Pricing
Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule H.R. 4581 - 340B PATIENTS Act of 2025 340B Reform 340B HHS Pilot Program Model Insurance Coverage of Prescription Drugs Direct-to-Patient Prescription Drug Purchase Platforms and insurance coverage PBM Reform P.L. 117-169 - Inflation Reduction Act (IRA) of 2022 Drug Pricing Medicare/Medicaid
Vaccine Policy, Coverage and Access Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule Drug Pricing PBM Reform H.R. 4581 - 340B PATIENTS Act of 2025 H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 2296 - National Defense Authorization Act (NDAA) for Fiscal Year 2026 S. 1053 - FIGHT China Act Cancer Research Centers for Disease Control and Prevention (CDC) Policies
Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule H.R. 4581 - 340B PATIENTS Act of 2025 340B Reform 340B HHS Pilot Program Model Insurance Coverage of Prescription Drugs Direct-to-Patient Prescription Drug Purchase Platforms and insurance coverage PBM Reform P.L. 117-169 - Inflation Reduction Act (IRA) of 2022 Drug Pricing Medicare/Medicaid
Vaccine Policy, Coverage and Access Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule Drug Pricing PBM Reform H.R. 4581 - 340B PATIENTS Act of 2025 H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 2296 - National Defense Authorization Act (NDAA) for Fiscal Year 2026 S. 1053 - FIGHT China Act Cancer Research Centers for Disease Control and Prevention (CDC) Policies
Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule H.R. 4581 - 340B PATIENTS Act of 2025 340B Reform 340B HHS Pilot Program Model Insurance Coverage of Prescription Drugs Direct-to-Patient Prescription Drug Purchase Platforms and insurance coverage PBM Reform P.L. 117-169 - Inflation Reduction Act (IRA) of 2022 Drug Pricing Medicare/Medicaid
Vaccine Policy, Coverage and Access Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule Drug Pricing PBM Reform H.R. 4581 - 340B PATIENTS Act of 2025 H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 2296 - National Defense Authorization Act (NDAA) for Fiscal Year 2026 S. 1053 - FIGHT China Act Cancer Research Centers for Disease Control and Prevention (CDC) Policies
Vaccine Policy, Coverage and Access HR 4317 - PMB Reform Act of 2025 Gavi Vaccines Alliance Issues HR 2214 - DRUG Act S 832 - EPIC Act of 2025 S 864 - HELP Copays ACT S 882 - Patients Before Middlemen Act Prescription Drug-Use-Related Software (PDURS): Digital Medicine Lyme Disease Issues Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients IRA Biosimilars Pause Fix, Biosimilar Legislation H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Orphan Drug Exemption, Pill Penalty, Biosimilar Pause Vaccine Coverage and Access Drug Pricing
Vaccine Policy, Coverage and Access Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule Drug Pricing PBM Reform H.R. 4581 - 340B PATIENTS Act of 2025 H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 2296 - National Defense Authorization Act (NDAA) for Fiscal Year 2026 S. 1053 - FIGHT China Act Cancer Research Centers for Disease Control and Prevention (CDC) Policies
Vaccine Policy, Coverage and Access Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule Drug Pricing PBM Reform H.R. 4581 - 340B PATIENTS Act of 2025 H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 2296 - National Defense Authorization Act (NDAA) for Fiscal Year 2026 S. 1053 - FIGHT China Act Cancer Research Centers for Disease Control and Prevention (CDC) Policies
Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule H.R. 4581 - 340B PATIENTS Act of 2025 340B Reform 340B HHS Pilot Program Model Insurance Coverage of Prescription Drugs Direct-to-Patient Prescription Drug Purchase Platforms and insurance coverage PBM Reform P.L. 117-169 - Inflation Reduction Act (IRA) of 2022 Drug Pricing Medicare/Medicaid
Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule H.R. 4581 - 340B PATIENTS Act of 2025 340B Reform 340B HHS Pilot Program Model Insurance Coverage of Prescription Drugs Direct-to-Patient Prescription Drug Purchase Platforms and insurance coverage PBM Reform P.L. 117-169 - Inflation Reduction Act (IRA) of 2022 Drug Pricing Medicare/Medicaid
Vaccine Policy, Coverage and Access HR 4317 - PMB Reform Act of 2025 Gavi Vaccines Alliance Issues HR 2214 - DRUG Act S 832 - EPIC Act of 2025 S 864 - HELP Copays ACT S 882 - Patients Before Middlemen Act Prescription Drug-Use-Related Software (PDURS): Digital Medicine Lyme Disease Issues Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients IRA Biosimilars Pause Fix, Biosimilar Legislation H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Orphan Drug Exemption, Pill Penalty, Biosimilar Pause Vaccine Coverage and Access Drug Pricing
Vaccine Policy, Coverage and Access Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule Drug Pricing PBM Reform H.R. 4581 - 340B PATIENTS Act of 2025 H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 2296 - National Defense Authorization Act (NDAA) for Fiscal Year 2026 S. 1053 - FIGHT China Act Cancer Research Centers for Disease Control and Prevention (CDC) Policies
Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule H.R. 4581 - 340B PATIENTS Act of 2025 340B Reform 340B HHS Pilot Program Model Insurance Coverage of Prescription Drugs Direct-to-Patient Prescription Drug Purchase Platforms and insurance coverage PBM Reform P.L. 117-169 - Inflation Reduction Act (IRA) of 2022 Drug Pricing Medicare/Medicaid
Vaccine Policy, Coverage and Access HR 4317 - PMB Reform Act of 2025 Gavi Vaccines Alliance Issues HR 2214 - DRUG Act S 832 - EPIC Act of 2025 S 864 - HELP Copays ACT S 882 - Patients Before Middlemen Act Prescription Drug-Use-Related Software (PDURS): Digital Medicine Lyme Disease Issues Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients IRA Biosimilars Pause Fix, Biosimilar Legislation H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Orphan Drug Exemption, Pill Penalty, Biosimilar Pause Vaccine Coverage and Access Drug Pricing
Vaccine Policy, Coverage and Access Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule Drug Pricing PBM Reform H.R. 4581 - 340B PATIENTS Act of 2025 H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 2296 - National Defense Authorization Act (NDAA) for Fiscal Year 2026 S. 1053 - FIGHT China Act Cancer Research Centers for Disease Control and Prevention (CDC) Policies
Vaccine Policy, Coverage and Access Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule Drug Pricing PBM Reform H.R. 4581 - 340B PATIENTS Act of 2025 H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 2296 - National Defense Authorization Act (NDAA) for Fiscal Year 2026 S. 1053 - FIGHT China Act Cancer Research Centers for Disease Control and Prevention (CDC) Policies
Vaccine Policy, Coverage and Access Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule Drug Pricing PBM Reform H.R. 4581 - 340B PATIENTS Act of 2025 H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 2296 - National Defense Authorization Act (NDAA) for Fiscal Year 2026 S. 1053 - FIGHT China Act Cancer Research Centers for Disease Control and Prevention (CDC) Policies
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of 2025 HR 1 - One Big Beautiful Bill Act CDC Reform Vaccine Policy Reconciliation Research & Development HR 946 - ORPHAN Cures Act HR 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program HR 2214 - DRUG Act HR 2450 - Prescription Drug Transparency and Affordability Act PL 117-328 Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Biosimilars Access, Reimbursement and Reform 340B Reform Prescription Drug User Fee Act (PDUFA) Inflation Reduction Act (IRA) Pill Penalty Vaccine Coverage and Access Intellectual Property Protections PBM Reform Cancer Policies Drug Pricing
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of 2025 HR 946 - ORPHAN Cures Act HR 2450 - Prescription Drug Transparency and Affordability Act Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients PBM Reform Medicaid Prescription Drug Access Digital Therapeutics
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of 2025 HR 946 - ORPHAN Cures Act HR 2450 - Prescription Drug Transparency and Affordability Act Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients PBM Reform Medicaid Prescription Drug Access Digital Therapeutics
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of 2025 HR 1 - One Big Beautiful Bill Act CDC Reform Vaccine Policy Reconciliation Research & Development HR 946 - ORPHAN Cures Act HR 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program HR 2214 - DRUG Act HR 2450 - Prescription Drug Transparency and Affordability Act PL 117-328 Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Biosimilars Access, Reimbursement and Reform 340B Reform Prescription Drug User Fee Act (PDUFA) Inflation Reduction Act (IRA) Pill Penalty Vaccine Coverage and Access Intellectual Property Protections PBM Reform Cancer Policies Drug Pricing
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of 2025 HR 1 - One Big Beautiful Bill Act CDC Reform Vaccine Policy Reconciliation Research & Development HR 946 - ORPHAN Cures Act HR 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program HR 2214 - DRUG Act HR 2450 - Prescription Drug Transparency and Affordability Act PL 117-328 Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Biosimilars Access, Reimbursement and Reform 340B Reform Prescription Drug User Fee Act (PDUFA) Inflation Reduction Act (IRA) Pill Penalty Vaccine Coverage and Access Intellectual Property Protections PBM Reform Cancer Policies Drug Pricing
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of 2025 HR 946 - ORPHAN Cures Act HR 2450 - Prescription Drug Transparency and Affordability Act Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients PBM Reform Medicaid Prescription Drug Access Digital Therapeutics
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 527 - Prescription Pricing for the People Act of 2025 S 832 - EPIC Act of 2025 S 864 - HELP Copays Act S 882 - Patients Before Middlemen Act S 1040 - Drug Competition Enhancement Act HR 946 - ORPHAN Cures Act HR 1492 - EPIC Act Biosimilars Access & Reimbursement 340B Reform 340B Access Act Inflation Reduction Act (IRA) Biosimilar Pause Inflation Reduction Act (IRA) Pill Penalty Vaccine Coverage Intellectual Property Protections PBM Reform Lower Cost More Transparency Act Bayh-Dole Act March-In Rights Cancer Policies Drug Pricing/Foreign Reference Pricing Digital Therapeutics Access & Reimbursement Patient Out of Pocket Costs
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 527 - Prescription Pricing for the People Act of 2025 S 832 - Epic Act of 2025 S 864 - HELP Copays Act S 882 - Patients Before Middlemen Act HR 946 - ORPHAN Cures Act PBM Reform Medicaid Prescription Drug Access
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 527 - Prescription Pricing for the People Act of 2025 S 832 - EPIC Act of 2025 S 864 - HELP Copays Act S 882 - Patients Before Middlemen Act S 1040 - Drug Competition Enhancement Act HR 946 - ORPHAN Cures Act HR 1492 - EPIC Act Biosimilars Access & Reimbursement 340B Reform 340B Access Act Inflation Reduction Act (IRA) Biosimilar Pause Inflation Reduction Act (IRA) Pill Penalty Vaccine Coverage Intellectual Property Protections PBM Reform Lower Cost More Transparency Act Bayh-Dole Act March-In Rights Cancer Policies Drug Pricing/Foreign Reference Pricing Digital Therapeutics Access & Reimbursement Patient Out of Pocket Costs
Vaccine Policy, Coverage and Access Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule Drug Pricing PBM Reform H.R. 4581 - 340B PATIENTS Act of 2025 H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 2296 - National Defense Authorization Act (NDAA) for Fiscal Year 2026 S. 1053 - FIGHT China Act Cancer Research Centers for Disease Control and Prevention (CDC) Policies
Vaccine Policy, Coverage and Access Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule Drug Pricing PBM Reform H.R. 4581 - 340B PATIENTS Act of 2025 H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 2296 - National Defense Authorization Act (NDAA) for Fiscal Year 2026 S. 1053 - FIGHT China Act Cancer Research Centers for Disease Control and Prevention (CDC) Policies
Vaccine Policy, Coverage and Access Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule Drug Pricing PBM Reform H.R. 4581 - 340B PATIENTS Act of 2025 H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 2296 - National Defense Authorization Act (NDAA) for Fiscal Year 2026 S. 1053 - FIGHT China Act Cancer Research Centers for Disease Control and Prevention (CDC) Policies
Access to Prescription Digital Therapeutics Act of 2025
Client: PFIZER INC. · Firm: PFIZER INC.
Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients PBM Reform S 1702 - Access to Prescription Digital Therapeutics Act of 2025 Digital Therapeutics
Access to Prescription Digital Therapeutics Act of 2025
Client: PFIZER INC. · Firm: PFIZER INC.
Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients PBM Reform S 1702 - Access to Prescription Digital Therapeutics Act of 2025 Digital Therapeutics
Access to Prescription Digital Therapeutics Act of 2025
Client: PFIZER INC. · Firm: PFIZER INC.
Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients PBM Reform S 1702 - Access to Prescription Digital Therapeutics Act of 2025 Digital Therapeutics
National Defense Authorization Act for Fiscal Year 2026
Client: PFIZER INC. · Firm: PFIZER INC.
Vaccine Policy, Coverage and Access Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule Drug Pricing PBM Reform H.R. 4581 - 340B PATIENTS Act of 2025 H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 2296 - National Defense Authorization Act (NDAA) for Fiscal Year 2026 S. 1053 - FIGHT China Act Cancer Research Centers for Disease Control and Prevention (CDC) Policies
National Defense Authorization Act for Fiscal Year 2026
Client: PFIZER INC. · Firm: PFIZER INC.
Vaccine Policy, Coverage and Access Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule Drug Pricing PBM Reform H.R. 4581 - 340B PATIENTS Act of 2025 H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 2296 - National Defense Authorization Act (NDAA) for Fiscal Year 2026 S. 1053 - FIGHT China Act Cancer Research Centers for Disease Control and Prevention (CDC) Policies
National Defense Authorization Act for Fiscal Year 2026
Client: PFIZER INC. · Firm: PFIZER INC.
Vaccine Policy, Coverage and Access Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule Drug Pricing PBM Reform H.R. 4581 - 340B PATIENTS Act of 2025 H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 2296 - National Defense Authorization Act (NDAA) for Fiscal Year 2026 S. 1053 - FIGHT China Act Cancer Research Centers for Disease Control and Prevention (CDC) Policies
Vaccine Policy, Coverage and Access Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule Drug Pricing PBM Reform H.R. 4581 - 340B PATIENTS Act of 2025 H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 2296 - National Defense Authorization Act (NDAA) for Fiscal Year 2026 S. 1053 - FIGHT China Act Cancer Research Centers for Disease Control and Prevention (CDC) Policies
Vaccine Policy, Coverage and Access Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule Drug Pricing PBM Reform H.R. 4581 - 340B PATIENTS Act of 2025 H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 2296 - National Defense Authorization Act (NDAA) for Fiscal Year 2026 S. 1053 - FIGHT China Act Cancer Research Centers for Disease Control and Prevention (CDC) Policies
Vaccine Policy, Coverage and Access Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule Drug Pricing PBM Reform H.R. 4581 - 340B PATIENTS Act of 2025 H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 2296 - National Defense Authorization Act (NDAA) for Fiscal Year 2026 S. 1053 - FIGHT China Act Cancer Research Centers for Disease Control and Prevention (CDC) Policies
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of 2025 HR 1 - One Big Beautiful Bill Act CDC Reform Vaccine Policy Reconciliation Research & Development HR 946 - ORPHAN Cures Act HR 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program HR 2214 - DRUG Act HR 2450 - Prescription Drug Transparency and Affordability Act PL 117-328 Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Biosimilars Access, Reimbursement and Reform 340B Reform Prescription Drug User Fee Act (PDUFA) Inflation Reduction Act (IRA) Pill Penalty Vaccine Coverage and Access Intellectual Property Protections PBM Reform Cancer Policies Drug Pricing
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of 2025 HR 946 - ORPHAN Cures Act HR 2450 - Prescription Drug Transparency and Affordability Act Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients PBM Reform Medicaid Prescription Drug Access Digital Therapeutics
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of 2025 HR 1 - One Big Beautiful Bill Act CDC Reform Vaccine Policy Reconciliation Research & Development HR 946 - ORPHAN Cures Act HR 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program HR 2214 - DRUG Act HR 2450 - Prescription Drug Transparency and Affordability Act PL 117-328 Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Biosimilars Access, Reimbursement and Reform 340B Reform Prescription Drug User Fee Act (PDUFA) Inflation Reduction Act (IRA) Pill Penalty Vaccine Coverage and Access Intellectual Property Protections PBM Reform Cancer Policies Drug Pricing
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 527 - Prescription Pricing for the People Act of 2025 S 832 - EPIC Act of 2025 S 864 - HELP Copays Act S 882 - Patients Before Middlemen Act S 1040 - Drug Competition Enhancement Act HR 946 - ORPHAN Cures Act HR 1492 - EPIC Act Biosimilars Access & Reimbursement 340B Reform 340B Access Act Inflation Reduction Act (IRA) Biosimilar Pause Inflation Reduction Act (IRA) Pill Penalty Vaccine Coverage Intellectual Property Protections PBM Reform Lower Cost More Transparency Act Bayh-Dole Act March-In Rights Cancer Policies Drug Pricing/Foreign Reference Pricing Digital Therapeutics Access & Reimbursement Patient Out of Pocket Costs
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 527 - Prescription Pricing for the People Act of 2025 S 832 - Epic Act of 2025 S 864 - HELP Copays Act S 882 - Patients Before Middlemen Act HR 946 - ORPHAN Cures Act PBM Reform Medicaid Prescription Drug Access
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of 2025 HR 946 - ORPHAN Cures Act HR 2450 - Prescription Drug Transparency and Affordability Act Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients PBM Reform Medicaid Prescription Drug Access Digital Therapeutics
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of 2025 HR 1 - One Big Beautiful Bill Act CDC Reform Vaccine Policy Reconciliation Research & Development HR 946 - ORPHAN Cures Act HR 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program HR 2214 - DRUG Act HR 2450 - Prescription Drug Transparency and Affordability Act PL 117-328 Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Biosimilars Access, Reimbursement and Reform 340B Reform Prescription Drug User Fee Act (PDUFA) Inflation Reduction Act (IRA) Pill Penalty Vaccine Coverage and Access Intellectual Property Protections PBM Reform Cancer Policies Drug Pricing
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of 2025 HR 946 - ORPHAN Cures Act HR 2450 - Prescription Drug Transparency and Affordability Act Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients PBM Reform Medicaid Prescription Drug Access Digital Therapeutics
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 527 - Prescription Pricing for the People Act of 2025 S 832 - EPIC Act of 2025 S 864 - HELP Copays Act S 882 - Patients Before Middlemen Act S 1040 - Drug Competition Enhancement Act HR 946 - ORPHAN Cures Act HR 1492 - EPIC Act Biosimilars Access & Reimbursement 340B Reform 340B Access Act Inflation Reduction Act (IRA) Biosimilar Pause Inflation Reduction Act (IRA) Pill Penalty Vaccine Coverage Intellectual Property Protections PBM Reform Lower Cost More Transparency Act Bayh-Dole Act March-In Rights Cancer Policies Drug Pricing/Foreign Reference Pricing Digital Therapeutics Access & Reimbursement Patient Out of Pocket Costs
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 527 - Prescription Pricing for the People Act of 2025 S 832 - Epic Act of 2025 S 864 - HELP Copays Act S 882 - Patients Before Middlemen Act HR 946 - ORPHAN Cures Act PBM Reform Medicaid Prescription Drug Access
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of 2025 HR 1 - One Big Beautiful Bill Act CDC Reform Vaccine Policy Reconciliation Research & Development HR 946 - ORPHAN Cures Act HR 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program HR 2214 - DRUG Act HR 2450 - Prescription Drug Transparency and Affordability Act PL 117-328 Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Biosimilars Access, Reimbursement and Reform 340B Reform Prescription Drug User Fee Act (PDUFA) Inflation Reduction Act (IRA) Pill Penalty Vaccine Coverage and Access Intellectual Property Protections PBM Reform Cancer Policies Drug Pricing
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of 2025 HR 946 - ORPHAN Cures Act HR 2450 - Prescription Drug Transparency and Affordability Act Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients PBM Reform Medicaid Prescription Drug Access Digital Therapeutics
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of 2025 HR 1 - One Big Beautiful Bill Act CDC Reform Vaccine Policy Reconciliation Research & Development HR 946 - ORPHAN Cures Act HR 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program HR 2214 - DRUG Act HR 2450 - Prescription Drug Transparency and Affordability Act PL 117-328 Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Biosimilars Access, Reimbursement and Reform 340B Reform Prescription Drug User Fee Act (PDUFA) Inflation Reduction Act (IRA) Pill Penalty Vaccine Coverage and Access Intellectual Property Protections PBM Reform Cancer Policies Drug Pricing
H.R. 9102 - Biotech Investment National Security Act (BINSA) Act: US Competitiveness, Biotechnology Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients FDA-2026-N-4699 - Expedited Investigational New Drug (IND) pilot program International Supply Chain Section 301 Investigation re: Germany Issues Foreign Freeriding Issues Non-Tariff Trade Barriers Global Health Competitiveness Issues Clinical Trial Issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
2026 · first_quarter · 1A
International Supply Chain Market Access Most Favored Nation Policies Foreign Freeriding Issues Non-Tariff Trade Barriers Competiveness Issues Trade Issues
Vaccine Coverage Pediatric Immunization Schedule Vaccine Injury Compensation Program Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 7837 - Most Favored Patient Act of 2026 Lyme Disease Issues 340B Issues Counterfeit Drugs Inflation Reduction Act (IRA) Prescription Drug User Fee Act (PDUFA) Drug Pricing PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 3510 - Biosimilar Inspection Modernization Act of 2025
Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Prescription Drug User Fee Act (PDUFA) 340B Issues Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage PBM Reform Counterfeit Drugs P.L. 117-169 - Inflation Reduction Act (IRA) of 2022 Drug Pricing Medicare/Medicaid Issues
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, U.S. Trade Representative (USTR)
2026 · second_quarter · Q2
H.R. 7391 - Community Health Center Drug Pricing Protection Act Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Vaccine Access and Coverage 340B Program Reform PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage Step Therapy Practices Drug Pricing Medicare/Medicaid Issues
Vaccine Coverage and Coverage Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Codification and Sec. 301 trade investigations FDA User Fee Agreements: 2027 PDUFA Cycle H.R. 7837 - Most Favored Patient Act of 2026 H.R. 7391 - Community Health Center Drug Pricing Protection Act 340B Program Reform Inflation Reduction Act (IRA) H.R. 8646 - Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriates Act, 2027 H.R. 9260 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriation Act, 2027 H.R. 5178 - Sickle Cell Disease Comprehensive Care Act H.R. 5526 - Biosimilars Red Tape Elimination Act H.R. 4930 - To Expand the Sharing of Information with Respect to Suspected Violations of Intellectual Property Rights in Trade H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act: IRA reforms Prior Authorization Step Therapy Practices FDA Modernization and Reforms Drug Pricing PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage
H.R. 9102 - Biotech Investment National Security Act (BINSA) Act: US Competitiveness, Biotechnology H.R. 4930 - To Expand the Sharing of Information with Respect to Suspected Violations of Intellectual Property Rights in Trade International Supply Chain Section 301 Investigation re: Germany Issues Market Access Most Favored Nation Policies Foreign Freeriding Issues Non-Tariff Trade Barriers Competitiveness Issues Trade Issues
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)
2026 · first_quarter · Q1
Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Prescription Drug User Fee Act (PDUFA) 340B Issues Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage PBM Reform Counterfeit Drugs P.L. 117-169 - Inflation Reduction Act (IRA) of 2022 Drug Pricing Medicare/Medicaid Issues
International Supply Chain Market Access Most Favored Nation Policies Foreign Freeriding Issues Non-Tariff Trade Barriers Competiveness Issues Trade Issues
Vaccine Coverage Pediatric Immunization Schedule Vaccine Injury Compensation Program Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 7837 - Most Favored Patient Act of 2026 Lyme Disease Issues 340B Issues Counterfeit Drugs Inflation Reduction Act (IRA) Prescription Drug User Fee Act (PDUFA) Drug Pricing PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 3510 - Biosimilar Inspection Modernization Act of 2025
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, U.S. Trade Representative (USTR)
2025 · fourth_quarter · 4A
Vaccine Policy, Coverage and Access Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule Drug Pricing PBM Reform H.R. 4581 - 340B PATIENTS Act of 2025 H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 2296 - National Defense Authorization Act (NDAA) for Fiscal Year 2026 S. 1053 - FIGHT China Act Cancer Research Centers for Disease Control and Prevention (CDC) Policies
Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule H.R. 4581 - 340B PATIENTS Act of 2025 340B Reform 340B HHS Pilot Program Model Insurance Coverage of Prescription Drugs Direct-to-Patient Prescription Drug Purchase Platforms and insurance coverage PBM Reform P.L. 117-169 - Inflation Reduction Act (IRA) of 2022 Drug Pricing Medicare/Medicaid
International Supply Chain Global Access Market Access Most Favored Nation Policies Tariffs Generics Foreign Freeriding Issues Non-Tariff Trade Barriers Trade Issues
Filing targets: Centers For Disease Control & Prevention (CDC), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, U.S. Trade Representative (USTR)
2025 · third_quarter · 3A
Vaccine Policy, Coverage and Access HR 4317 - PMB Reform Act of 2025 Gavi Vaccines Alliance Issues HR 2214 - DRUG Act S 832 - EPIC Act of 2025 S 864 - HELP Copays ACT S 882 - Patients Before Middlemen Act Prescription Drug-Use-Related Software (PDURS): Digital Medicine Lyme Disease Issues Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients IRA Biosimilars Pause Fix, Biosimilar Legislation H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Orphan Drug Exemption, Pill Penalty, Biosimilar Pause Vaccine Coverage and Access Drug Pricing
Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients PBM Reform S 1702 - Access to Prescription Digital Therapeutics Act of 2025 Digital Therapeutics
2025 · fourth_quarter · 4A
Vaccine Policy, Coverage and Access Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule Drug Pricing PBM Reform H.R. 4581 - 340B PATIENTS Act of 2025 H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 2296 - National Defense Authorization Act (NDAA) for Fiscal Year 2026 S. 1053 - FIGHT China Act Cancer Research Centers for Disease Control and Prevention (CDC) Policies
Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule H.R. 4581 - 340B PATIENTS Act of 2025 340B Reform 340B HHS Pilot Program Model Insurance Coverage of Prescription Drugs Direct-to-Patient Prescription Drug Purchase Platforms and insurance coverage PBM Reform P.L. 117-169 - Inflation Reduction Act (IRA) of 2022 Drug Pricing Medicare/Medicaid
2025 · third_quarter · 3A
Vaccine Policy, Coverage and Access HR 4317 - PMB Reform Act of 2025 Gavi Vaccines Alliance Issues HR 2214 - DRUG Act S 832 - EPIC Act of 2025 S 864 - HELP Copays ACT S 882 - Patients Before Middlemen Act Prescription Drug-Use-Related Software (PDURS): Digital Medicine Lyme Disease Issues Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients IRA Biosimilars Pause Fix, Biosimilar Legislation H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Orphan Drug Exemption, Pill Penalty, Biosimilar Pause Vaccine Coverage and Access Drug Pricing
Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients PBM Reform S 1702 - Access to Prescription Digital Therapeutics Act of 2025 Digital Therapeutics
2025 · fourth_quarter · Q4
Vaccine Policy, Coverage and Access Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule Drug Pricing PBM Reform H.R. 4581 - 340B PATIENTS Act of 2025 H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 2296 - National Defense Authorization Act (NDAA) for Fiscal Year 2026 S. 1053 - FIGHT China Act Cancer Research Centers for Disease Control and Prevention (CDC) Policies
Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule H.R. 4581 - 340B PATIENTS Act of 2025 340B Reform 340B HHS Pilot Program Model Insurance Coverage of Prescription Drugs Direct-to-Patient Prescription Drug Purchase Platforms and insurance coverage PBM Reform P.L. 117-169 - Inflation Reduction Act (IRA) of 2022 Drug Pricing Medicare/Medicaid
2025 · second_quarter · 2A
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of 2025 HR 1 - One Big Beautiful Bill Act CDC Reform Vaccine Policy Reconciliation Research & Development HR 946 - ORPHAN Cures Act HR 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program HR 2214 - DRUG Act HR 2450 - Prescription Drug Transparency and Affordability Act PL 117-328 Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Biosimilars Access, Reimbursement and Reform 340B Reform Prescription Drug User Fee Act (PDUFA) Inflation Reduction Act (IRA) Pill Penalty Vaccine Coverage and Access Intellectual Property Protections PBM Reform Cancer Policies Drug Pricing
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of 2025 HR 946 - ORPHAN Cures Act HR 2450 - Prescription Drug Transparency and Affordability Act Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients PBM Reform Medicaid Prescription Drug Access Digital Therapeutics
2025 · third_quarter · Q3
Vaccine Policy, Coverage and Access HR 4317 - PMB Reform Act of 2025 Gavi Vaccines Alliance Issues HR 2214 - DRUG Act S 832 - EPIC Act of 2025 S 864 - HELP Copays ACT S 882 - Patients Before Middlemen Act Prescription Drug-Use-Related Software (PDURS): Digital Medicine Lyme Disease Issues Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients IRA Biosimilars Pause Fix, Biosimilar Legislation H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Orphan Drug Exemption, Pill Penalty, Biosimilar Pause Vaccine Coverage and Access Drug Pricing
Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients PBM Reform S 1702 - Access to Prescription Digital Therapeutics Act of 2025 Digital Therapeutics
2025 · second_quarter · 2A
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of 2025 HR 1 - One Big Beautiful Bill Act CDC Reform Vaccine Policy Reconciliation Research & Development HR 946 - ORPHAN Cures Act HR 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program HR 2214 - DRUG Act HR 2450 - Prescription Drug Transparency and Affordability Act PL 117-328 Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Biosimilars Access, Reimbursement and Reform 340B Reform Prescription Drug User Fee Act (PDUFA) Inflation Reduction Act (IRA) Pill Penalty Vaccine Coverage and Access Intellectual Property Protections PBM Reform Cancer Policies Drug Pricing
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of 2025 HR 946 - ORPHAN Cures Act HR 2450 - Prescription Drug Transparency and Affordability Act Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients PBM Reform Medicaid Prescription Drug Access Digital Therapeutics
2025 · second_quarter · Q2
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of 2025 HR 1 - One Big Beautiful Bill Act CDC Reform Vaccine Policy Reconciliation Research & Development HR 946 - ORPHAN Cures Act HR 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program HR 2214 - DRUG Act HR 2450 - Prescription Drug Transparency and Affordability Act PL 117-328 Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Biosimilars Access, Reimbursement and Reform 340B Reform Prescription Drug User Fee Act (PDUFA) Inflation Reduction Act (IRA) Pill Penalty Vaccine Coverage and Access Intellectual Property Protections PBM Reform Cancer Policies Drug Pricing
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of 2025 HR 946 - ORPHAN Cures Act HR 2450 - Prescription Drug Transparency and Affordability Act Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients PBM Reform Medicaid Prescription Drug Access Digital Therapeutics
2025 · first_quarter · Q1
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 527 - Prescription Pricing for the People Act of 2025 S 832 - EPIC Act of 2025 S 864 - HELP Copays Act S 882 - Patients Before Middlemen Act S 1040 - Drug Competition Enhancement Act HR 946 - ORPHAN Cures Act HR 1492 - EPIC Act Biosimilars Access & Reimbursement 340B Reform 340B Access Act Inflation Reduction Act (IRA) Biosimilar Pause Inflation Reduction Act (IRA) Pill Penalty Vaccine Coverage Intellectual Property Protections PBM Reform Lower Cost More Transparency Act Bayh-Dole Act March-In Rights Cancer Policies Drug Pricing/Foreign Reference Pricing Digital Therapeutics Access & Reimbursement Patient Out of Pocket Costs
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 527 - Prescription Pricing for the People Act of 2025 S 832 - Epic Act of 2025 S 864 - HELP Copays Act S 882 - Patients Before Middlemen Act HR 946 - ORPHAN Cures Act PBM Reform Medicaid Prescription Drug Access
2024 · fourth_quarter · 4A
Comprehensive Corporate Tax Reform Tax Cuts and Jobs Act (TCJA) VICP Reform and Excise Tax Vaccine Injury Compensation Fund VICP Transition Comprehensive Federal Tax Reform
Inflation Reduction Act (IRA) HR 7174 - Ensuring Pathways to Innovative Cures (EPIC) Act Medicare Price Setting Drug Shortages Global Access to Medicines Trade-Related Aspects of Intellectual Property Rights (IPR) March-in Framework Guidance and Policies S 79/ HR 1717 - Interagency Patent Coordination and Improvement Act of 2023 S 142 - Preserve Access to Affordable Generics and Biosimilars Act HR 6986 - To address patent thickets S 150 - Affordable Prescriptions for Patients Act of 2023 S 2780/ HR 5429 - Medication Affordability and Patent Integrity Act Antimicrobial Resistance PBM Transparency and Reform S 1542 - Delinking Revenue from Unfair Gouging (DRUG) Act S 3430 - Better Mental Health Care, Lower-Cost Drugs and Extenders Act S 2973 - Modernizing and Ensuring PMB Accountability Act 340B Reform HR 8574 - 340B Affording Care for Communities and Ensuring a Strong Safety-net (ACCESS) Act
2024 · first_quarter · 1A
PBM Transparency and Reform: S1375/HH830 - Help Ensure Lower Patient (HELP) Copays Act S1542/HR6283 - Delinking Revenue from Unfair Gouging (DRUG) Act S2973 - Modernizing and Ensuring PBM Accountability Act S3430 - Better Mental Health Care, Lower Cost Drugs, and Extenders Act HR5378 - Lower Costs More Transparency Act Inflation Reduction Act /Medicare Price Setting 340B Reform Cell and Gene Therapy Access Model HR1458 - Access to Prescription Digital Therapeutics Act of 2023
Pandemic Preparedness/PAHPA Drug Pricing/Inflation Reduction Act: HR7174; Medicare Price Setting
March-in Framework Guidance and Policies IP Issues Digital Patent Thickets and Product Hopping
2024 · fourth_quarter · 4A
Comprehensive Corporate Tax Reform Tax Cuts and Jobs Act (TCJA) VICP Reform and Excise Tax Vaccine Injury Compensation Fund VICP Transition Comprehensive Federal Tax Reform
Inflation Reduction Act (IRA) HR 7174 - Ensuring Pathways to Innovative Cures (EPIC) Act Medicare Price Setting Drug Shortages Global Access to Medicines Trade-Related Aspects of Intellectual Property Rights (IPR) March-in Framework Guidance and Policies S 79/ HR 1717 - Interagency Patent Coordination and Improvement Act of 2023 S 142 - Preserve Access to Affordable Generics and Biosimilars Act HR 6986 - To address patent thickets S 150 - Affordable Prescriptions for Patients Act of 2023 S 2780/ HR 5429 - Medication Affordability and Patent Integrity Act Antimicrobial Resistance PBM Transparency and Reform S 1542 - Delinking Revenue from Unfair Gouging (DRUG) Act S 3430 - Better Mental Health Care, Lower-Cost Drugs and Extenders Act S 2973 - Modernizing and Ensuring PMB Accountability Act 340B Reform HR 8574 - 340B Affording Care for Communities and Ensuring a Strong Safety-net (ACCESS) Act
2024 · fourth_quarter · 4A
Inflation Reduction Act (IRA) HR 7174 - Ensuring Pathways to Innovative Cures (EPIC) Act Medicare Price Setting Drug Shortages Global Access to Medicines Trade-Related Aspects of Intellectual Property Rights (IPR) March-in Framework Guidance and Policies S 79/ HR 1717 - Interagency Patent Coordination and Improvement Act of 2023 S 142 - Preserve Access to Affordable Generics and Biosimilars Act HR 6986 - To address patent thickets S 150 - Affordable Prescriptions for Patients Act of 2023 S 2780/ HR 5429 - Medication Affordability and Patent Integrity Act Antimicrobial Resistance PBM Transparency and Reform S 1542 - Delinking Revenue from Unfair Gouging (DRUG) Act S 3430 - Better Mental Health Care, Lower-Cost Drugs and Extenders Act S 2973 - Modernizing and Ensuring PMB Accountability Act 340B Reform HR 8574 - 340B Affording Care for Communities and Ensuring a Strong Safety-net (ACCESS) Act
Comprehensive Corporate Tax Reform Tax Cuts and Jobs Act (TCJA) VICP Reform and Excise Tax Vaccine Injury Compensation Fund VICP Transition Comprehensive Federal Tax Reform
2024 · fourth_quarter · 4A
Comprehensive Corporate Tax Reform Tax Cuts and Jobs Act (TCJA) VICP Reform and Excise Tax Vaccine Injury Compensation Fund VICP Transition Comprehensive Federal Tax Reform
Inflation Reduction Act (IRA) HR 7174 - Ensuring Pathways to Innovative Cures (EPIC) Act Medicare Price Setting Drug Shortages Global Access to Medicines Trade-Related Aspects of Intellectual Property Rights (IPR) March-in Framework Guidance and Policies S 79/ HR 1717 - Interagency Patent Coordination and Improvement Act of 2023 S 142 - Preserve Access to Affordable Generics and Biosimilars Act HR 6986 - To address patent thickets S 150 - Affordable Prescriptions for Patients Act of 2023 S 2780/ HR 5429 - Medication Affordability and Patent Integrity Act Antimicrobial Resistance PBM Transparency and Reform S 1542 - Delinking Revenue from Unfair Gouging (DRUG) Act S 3430 - Better Mental Health Care, Lower-Cost Drugs and Extenders Act S 2973 - Modernizing and Ensuring PMB Accountability Act 340B Reform HR 8574 - 340B Affording Care for Communities and Ensuring a Strong Safety-net (ACCESS) Act
2024 · fourth_quarter · Q4
Inflation Reduction Act (IRA) HR 7174 - Ensuring Pathways to Innovative Cures (EPIC) Act Medicare Price Setting Drug Shortages Global Access to Medicines Trade-Related Aspects of Intellectual Property Rights (IPR) March-in Framework Guidance and Policies S 79/ HR 1717 - Interagency Patent Coordination and Improvement Act of 2023 S 142 - Preserve Access to Affordable Generics and Biosimilars Act HR 6986 - To address patent thickets S 150 - Affordable Prescriptions for Patients Act of 2023 S 2780/ HR 5429 - Medication Affordability and Patent Integrity Act Antimicrobial Resistance PBM Transparency and Reform S 1542 - Delinking Revenue from Unfair Gouging (DRUG) Act S 3430 - Better Mental Health Care, Lower-Cost Drugs and Extenders Act S 2973 - Modernizing and Ensuring PMB Accountability Act 340B Reform HR 8574 - 340B Affording Care for Communities and Ensuring a Strong Safety-net (ACCESS) Act
Comprehensive Corporate Tax Reform Tax Cuts and Jobs Act (TCJA) VICP Reform and Excise Tax Vaccine Injury Compensation Fund VICP Transition Comprehensive Federal Tax Reform
2024 · third_quarter · 3A
Comprehensive Corporate Tax Reform Tax Cuts and Jobs Act (TCJA) VICP Reform and Excise Tax VICP Transition Comprehensive Federal Tax Reform
VICP Reform and Excise Tax Inflation Reduction Act (IRA) HR7174 - Ensuring Pathways to Innovative Cures (EPIC) Act Medicare Price Setting Part D Payer Utilization Management Drug Shortages S2916 - Prescription Information Modernization Act of 2023 Vaccines, Clinical Trials and Coverage S2305 - Biosimilar Red Tape Elimination Act Biosimilar Access and Interchangeability HR 2666 - Medicaid Value Based Payments for Patients (MVP) Act HR 4758 - Accelerating Kids Access to Care Act HR 7384 - Rare Pediatric Disease Priority Review (PRV) Voucher Trade-Related Aspects of Intellectual Property Rights March-in Framework Guidance and Policies S.79 - Interagency Patent Coordination and Improvement Act of 2023 S.142 - Preserve Access to Affordable Generics and Biosimilars Act S.150 - Affordable Prescriptions for Patients Act of 2023 S.2780 - Medication Affordability and Patent Integrity Act Digital: Data Flows and Digital Trade
2024 · third_quarter · Q3
Comprehensive Corporate Tax Reform Tax Cuts and Jobs Act (TCJA) VICP Reform and Excise Tax VICP Transition Comprehensive Federal Tax Reform
VICP Reform and Excise Tax Inflation Reduction Act (IRA) HR7174 - Ensuring Pathways to Innovative Cures (EPIC) Act Medicare Price Setting Part D Payer Utilization Management Drug Shortages S2916 - Prescription Information Modernization Act of 2023 Vaccines, Clinical Trials and Coverage S2305 - Biosimilar Red Tape Elimination Act Biosimilar Access and Interchangeability HR 2666 - Medicaid Value Based Payments for Patients (MVP) Act HR 4758 - Accelerating Kids Access to Care Act HR 7384 - Rare Pediatric Disease Priority Review (PRV) Voucher Trade-Related Aspects of Intellectual Property Rights March-in Framework Guidance and Policies S.79 - Interagency Patent Coordination and Improvement Act of 2023 S.142 - Preserve Access to Affordable Generics and Biosimilars Act S.150 - Affordable Prescriptions for Patients Act of 2023 S.2780 - Medication Affordability and Patent Integrity Act Digital: Data Flows and Digital Trade
2024 · second_quarter · Q2
VICP Reform and Excise Tax, VICP Transition Inflation Reduction Act (IRA)/Medicare Price Setting HR7174 - Ensuring Pathways to Innovative Cures (EPIC) Act Medicare Price Setting Drug Shortages Antimicrobial Resistance (AMR) Policy S.2305 - Biosimilar Red Tape Elimination Act Biosimilar Access and Interchangeability IRA Mitigation H.R. 4925 - EPIC Act
Comprehensive Corporate Tax Reform VICP Reform and Excise Tax, VICP Transition
IP Issues: Trade-Related Aspects of Intellectual Property Rights March-in Framework Guidance and Policies Digital: S2916 - Digital Communication of Prescribing Information for Drugs
2024 · first_quarter · Q1
PBM Transparency and Reform: S1375/HH830 - Help Ensure Lower Patient (HELP) Copays Act S1542/HR6283 - Delinking Revenue from Unfair Gouging (DRUG) Act S2973 - Modernizing and Ensuring PBM Accountability Act S3430 - Better Mental Health Care, Lower Cost Drugs, and Extenders Act HR5378 - Lower Costs More Transparency Act Inflation Reduction Act /Medicare Price Setting 340B Reform Cell and Gene Therapy Access Model HR1458 - Access to Prescription Digital Therapeutics Act of 2023
March-in Framework Guidance and Policies IP Issues Digital Patent Thickets and Product Hopping
Pandemic Preparedness/PAHPA Drug Pricing/Inflation Reduction Act: HR7174; Medicare Price Setting
2023 · fourth_quarter · Q4
Drug Pricing Support of Biosimilars Out-of-Pocket Costs Rebate Reform Vaccine Infrastructure/ Excise Tax PDUFA Pandemic Preparedness/PAHPA
Medicare Part D Rebate Reform- PBMs Out-Of-Pocket Costs Government Negotiation on Medicare Antimicrobial Resistance March-In
TRIPS Waiver Bayh-Dole March-in-Rights General IP Issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), Office of the Vice President of the United States, SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
2023 · third_quarter · Q3
Medicare Part D Rebate Reform- PBMs Out-Of-Pocket Costs Government negotiation on Medicare Antimicrobial Resistance March-In
Drug Pricing Support of Biosimilars Out-of-Pocket Costs Rebate Reform Vaccine Infrastructure/ Excise Tax PDUFA Pandemic Preparedness/PAHPA
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), Office of the Vice President of the United States, SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
2023 · second_quarter · Q2
Medicare Part D Rebate Reform- PBMs Out-Of-Pocket Costs Government negotiation on Medicare Antimicrobial Resistance March-In
Drug Pricing Support of Biosimilars Out-of-Pocket Costs Rebate Reform Vaccine Infrastructure/ Excise Tax PDUFA Pandemic Preparedness/PAHPA
TRIPS Waiver Bayh-Dole March-in-Rights General IP Issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), Office of the Vice President of the United States, SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
2023 · first_quarter · Q1
Drug Pricing Support of Biosimilars Out-of-Pocket Costs Rebate Reform Vaccine Infrastructure/ Excise Tax PDUFA Pandemic Preparedness/PAHPA
TRIPS Waiver Bayh-Dole Marc-in-Rights General IP Issues
Medicare Part D Rebate Reform- PMBs Out-Of-Pocket Costs Government negotiation on Medicare Antimicrobial Resistance March-In
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), Office of the Vice President of the United States, SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
2022 · second_quarter · 2A
Medicare Part D support for access to treatments for obesity Coverage Gap Rebate Reform Out-of-Pocket Costs Government Negotiation in Medicare
TRIPS Waiver General IP Issues Bayh-Dole March-In Rights
Drug Pricing Support of Biosimilars Out-of-Pocket Costs Rebate Reform Vaccine Infrastructure/HR 3656 Excise Tax- S.3087 Antimicrobial Resistance/HR 3932/PASTEUR Act COVID Relief Package/Appropriations PDUFA
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), Office of the Vice President of the United States, SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
2022 · first_quarter · 1A
TRIPS Waiver General IP Issues Bayh-Dole March-In Rights
Medicare Part D Coverage Gap Rebate Reform Out-of-Pocket Costs Government Negotiation in Medicare
Drug Pricing Biosimilars Out-of-Pocket Costs Rebate Reform Vaccine Infrastructure/HR 3656 Excise Tax Antimicrobial Resistance/HR 3932 COVID Relief Package/Appropriations PDUFA
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), Office of the Vice President of the United States, SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
2022 · fourth_quarter · Q4
Drug Pricing Support of Biosimilars Out-of-Pocket Costs Rebate Reform Vaccine Infrastructure/HR 3656 Excise Tax- S.3087 Antimicrobial Resistance/HR 3932/PASTEUR Act COVID Relief Package/Appropriations PDUFA
Medicare Part D support for access to treatments for obesity Coverage Gap Rebate Reform Out-of-Pocket Costs Government Negotiation in Medicare
NAFTA/USMCA Foreign Market Access issues (including IPR) International Supply Chain/Buy America - harmonize international drug manufacturing standards. Global Access to Medicines
2022 · third_quarter · Q3
Drug Pricing Support of Biosimilars Out-of-Pocket Costs Rebate Reform Vaccine Infrastructure/HR 3656 Excise Tax- S.3087 Antimicrobial Resistance/HR 3932/PASTEUR Act COVID Relief Package/Appropriations PDUFA
TRIPS Waiver General IP Issues Bayh-Dole March-In Rights
Medicare Part D support for access to treatments for obesity Coverage Gap Rebate Reform Out-of-Pocket Costs Government Negotiation in Medicare
2022 · second_quarter · 2A
TRIPS Waiver General IP Issues Bayh-Dole March-In Rights
Medicare Part D support for access to treatments for obesity Coverage Gap Rebate Reform Out-of-Pocket Costs Government Negotiation in Medicare
Drug Pricing Support of Biosimilars Out-of-Pocket Costs Rebate Reform Vaccine Infrastructure/HR 3656 Excise Tax- S.3087 Antimicrobial Resistance/HR 3932/PASTEUR Act COVID Relief Package/Appropriations PDUFA
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), Office of the Vice President of the United States, SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
2022 · first_quarter · 1A
TRIPS Waiver General IP Issues Bayh-Dole March-In Rights
Medicare Part D Coverage Gap Rebate Reform Out-of-Pocket Costs Government Negotiation in Medicare
Drug Pricing Biosimilars Out-of-Pocket Costs Rebate Reform Vaccine Infrastructure/HR 3656 Excise Tax Antimicrobial Resistance/HR 3932 COVID Relief Package/Appropriations PDUFA
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), Office of the Vice President of the United States, SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
2022 · second_quarter · Q2
TRIPS Waiver General IP Issues Bayh-Dole March-In Rights
Drug Pricing Support of Biosimilars Out-of-Pocket Costs Rebate Reform Vaccine Infrastructure/HR 3656 Excise Tax- S.3087 Antimicrobial Resistance/HR 3932/PASTEUR Act COVID Relief Package/Appropriations PDUFA
Medicare Part D support for access to treatments for obesity Coverage Gap Rebate Reform Out-of-Pocket Costs Government Negotiation in Medicare
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), Office of the Vice President of the United States, SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
2022 · first_quarter · Q1
TRIPS Waiver General IP Issues Bayh-Dole March-In Rights
Drug Pricing Biosimilars Out-of-Pocket Costs Rebate Reform Vaccine Infrastructure/HR 3656 Excise Tax Antimicrobial Resistance/HR 3932 COVID Relief Package/Appropriations PDUFA
Medicare Part D Coverage Gap Rebate Reform Out-of-Pocket Costs Government Negotiation in Medicare
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), Office of the Vice President of the United States, SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
2021 · first_quarter · 1A
Drug Pricing Biosimilars Drug Shortages Out-of-Pocket Costs Rebate Reform Vaccine Infrastructure Drug Importation
TRIPS Waiver
Medicare Part D Coverage Gap Rebate Reform Out-of-Pocket Costs Price Transparency International Reference Pricing/Most Favored Nations
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), Office of the Vice President of the United States, SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
2021 · fourth_quarter · Q4
NAFTA/USMCA Foreign Market Access issues (including IPR) International Supply Chain/Buy America
Medicare Part D Coverage Gap Rebate Reform Out-of-Pocket Costs International Reference Pricing/Most Favored Nations
Drug Pricing Biosimilars Out-of-Pocket Costs Rebate Reform Vaccine Infrastructure Antimicrobial Resistance
2021 · third_quarter · Q3
Medicare Part D Coverage Gap Rebate Reform Out-of-Pocket Costs International Reference Pricing/Most Favored Nations
Drug Pricing Biosimilars Out-of-Pocket Costs Rebate Reform Vaccine Infrastructure Antimicrobial Resistance
TRIPS Waiver
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), Office of the Vice President of the United States, SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
2021 · second_quarter · Q2
Drug Pricing Biosimilars Drug Shortages Out-of-Pocket Costs Rebate Reform Vaccine Infrastructure Antimicrobial Resistance
Medicare Part D Coverage Gap Rebate Reform Out-of-Pocket Costs International Reference Pricing/Most Favored Nations
TRIPS Waiver
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), Office of the Vice President of the United States, SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
2021 · first_quarter · Q1
Drug Pricing Biosimilars Drug Shortages Out-of-Pocket Costs Rebate Reform Vaccine Infrastructure Drug Importation
Medicare Part D Coverage Gap Rebate Reform Out-of-Pocket Costs Price Transparency International Reference Pricing/Most Favored Nations
TRIPS Waiver
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), Office of the Vice President of the United States, SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
2020 · fourth_quarter · Q4
Medicare Part D Coverage Gap Rebate Reform Out of Pocket Costs Price Transparency International Reference Pricing/Most Favored Nations
Drug Pricing Biosimilars Drug Shortages Out of Pocket Costs Rebate Reform Vaccine Infrastructure Drug Importation
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), Office of the Vice President of the United States, SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
2020 · third_quarter · Q3
Foreign Market Access Issues (including IPR) NAFTA/USMCA International Supply Chain/Buy America U.S.- U.K. Trade Negotiations U.S. - Kenya FTA
Medicare Part D Coverage Gap Rebate Reform Out of Pocket Costs Value Based Arrangements Price Transparency International Reference Pricing/Most Favored Nations
Drug Pricing Biosimilars Drug Shortages Out of Pocket Costs Value Based Arrangements Rebate Reform Vaccine Infrastructure Drug Importation
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), Office of the Vice President of the United States, SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
2020 · second_quarter · Q2
U.S.- Japan Trade Negotiations Foreign Market Access Issues NAFTA/USMCA International Supply Chain/Buy America U.S.- U.K. Trade Negotiations U.S. - Kenya FTA
Drug Pricing Biosimilars Drug Shortages Out of Pocket Costs Value Based Arrangements Rebate Reform Vaccine Infrastructure
Medicare Part D Coverage Gap Rebate Reform Out of Pocket Costs Value Based Arrangements Price Transparency
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), Office of the Vice President of the United States, SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
2020 · first_quarter · Q1
Medicare Part D Coverage Gap Rebate Reform Out of Pocket Costs Value Based Arrangements Price Transparency
U.S.- Japan Trade Negotiations China Trade Negotiations Foreign Market Access Issues NAFTA/USMCA International Supply Chain/Buy America U.S.- U.K. Trade Negotiations U.S. - Kenya FTA
Drug Pricing Biosimilars Drug Shortages Out of Pocket Costs Value Based Arrangements Rebate Reform
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), Office of the Vice President of the United States, SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
2019 · fourth_quarter · 4A
U.S.- Japan Trade Negotiations China Trade Negotiations NAFTA/USMCA Foreign Market Access Issues
Medicare Part D Coverage Gap Rebate Reform Out of Pocket Costs Value Based Arrangements Price Transparency
Drug Pricing Biosimilars Drug Shortages Out of Pocket Costs Value Based Arrangements Rebate Reform
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), Office of the Vice President of the United States, SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
2019 · fourth_quarter · Q4
U.S.- Japan Trade Negotiations China Trade Negotiations NAFTA/USMCA Foreign Market Access Issues
Medicare Part D Coverage Gap Rebate Reform Out of Pocket Costs Value Based Arrangements Price Transparency
Drug Pricing Biosimilars Drug Shortages Out of Pocket Costs Value Based Arrangements Rebate Reform
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), Office of the Vice President of the United States, SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
2019 · third_quarter · Q3
Drug Pricing Biosimilars Drug Shortages Out of Pocket Costs Value Based Arrangements Rebate Reform
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), Office of the Vice President of the United States, SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
2019 · second_quarter · Q2
Drug Pricing Biosimilars Drug Shortages Out of Pocket Costs Value Based Arrangements Rebate Reform
Medicare Part D Coverage Gap Rebate Reform Out of Pocket Costs Value Based Arrangements Price Transparency
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), Office of the Vice President of the United States, SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
2019 · first_quarter · 1A
Drug Pricing Biosimilars Drug Shortages Out of Pocket Costs Value Based Arrangements Rebate Reform
Medicare Part D Coverage Gap Rebate Reform Out of Pocket Costs Value Based Arrangements
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), Office of the Vice President of the United States, SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
2019 · first_quarter · Q1
Medicare Part D Coverage Gap Rebate Reform Out of Pocket Costs Value Based Arrangements
Drug Pricing Biosimilars Drug Shortages Out of Pocket Costs Value Based Arrangements Rebate Reform
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), Office of the Vice President of the United States, SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
2018 · third_quarter · 3A
Creates Act Transferable exclusivity
Drug Pricing Antibiotic Resistance/incentives Drug Shortages Reimbursement for products treating Sickle Cell Disease PAHPA
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of the Vice President of the United States, SENATE, Treasury, Dept of, White House Office
2018 · third_quarter · Q3
Drug Pricing Antibiotic Resistance/incentives Drug Shortages Reimbursement for products treating Sickle Cell Disease PAHPA
Creates Act Transferable exclusivity
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of the Vice President of the United States, SENATE, Treasury, Dept of, White House Office
2018 · second_quarter · 2A
Creates Act Patent Settlements Transferable exclusivity
Prescription Drug Abuse
Drug Pricing Biosimilars Reimbursement Antibiotic Resistance/incentives Drug Shortages Reimbursement for products treating Sickle Cell Disease PAHPA
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Natl Security Council (NSC), Office of the Vice President of the United States, Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
2018 · second_quarter · 2A
Creates Act Patent Settlements Transferable exclusivity
Drug Pricing Biosimilars Reimbursement Antibiotic Resistance/incentives Drug Shortages Reimbursement for products treating Sickle Cell Disease PAHPA
Prescription Drug Abuse
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Natl Security Council (NSC), Office of the Vice President of the United States, Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
2018 · second_quarter · Q2
Creates Act Patent Settlements Transferable exclusivity
Drug Pricing Biosimilars Reimbursement Antibiotic Resistance/incentives Drug Shortages Reimbursement for products treating Sickle Cell Disease PAHPA
Prescription Drug Abuse
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Natl Security Council (NSC), Office of the Vice President of the United States, Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
International Supply Chain Global Access Most Favored Nation Policies Tariffs Non-Tariff Trade Barriers United States-Mexico-Canada Agreement (USMCA)
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Treasury, Dept of, U.S. Trade Representative (USTR)
International Supply Chain Global Access Market Access Most Favored Nation Policies Tariffs Generics Foreign Freeriding Issues Non-Tariff Trade Barriers Trade Issues
Filing targets: Centers For Disease Control & Prevention (CDC), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, U.S. Trade Representative (USTR)
International Supply Chain Global Access Most Favored Nation Policies Tariffs Non-Tariff Trade Barriers United States-Mexico-Canada Agreement (USMCA)
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Treasury, Dept of, U.S. Trade Representative (USTR)
International Supply Chain Global Access Market Access Most Favored Nation Policies Tariffs Generics Foreign Freeriding Issues Non-Tariff Trade Barriers Trade Issues
Filing targets: Centers For Disease Control & Prevention (CDC), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, U.S. Trade Representative (USTR)
International Supply Chain Global Access Tariffs Non-Tariff Trade Barriers
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR)
International Supply Chain Global Access Most Favored Nation Policies Tariffs Non-Tariff Trade Barriers United States-Mexico-Canada Agreement (USMCA)
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Treasury, Dept of, U.S. Trade Representative (USTR)
International Supply Chain Global Access Tariffs Non-Tariff Trade Barriers
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR)
International Supply Chain Global Access Tariffs Non-Tariff Trade Barriers
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR)
HR 2213 - Authorize the President to Enter Into Trade Agreements for the Reciprocal Elimination of Duties or Other Import Restrictions with Respect to Medical Goods Medical Supply Chain Resiliency Act International Supply Chain Tariffs Non-Tariff Trade Barriers
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR), White House Office
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR), White House Office
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR), White House Office
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR), White House Office
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR), White House Office
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR), White House Office
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR), White House Office
S723/HR1458 - Access to Prescription Digital Therapeutics Act HR8816 - American Medical Innovation and Investment Act of 2024 PBM Transparency and Reform S1542/HR6283 - Delinking Revenue from Unfair Gouging (DRUG) Act HR2880 - Protecting Patients Against PBM Abuses Act HR5378 - Lower Costs More Transparency Act 340B Reform HR8574 - 340B Affording Care for Communities and Ensuring a Strong Safety-net (ACCESS) Act
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS)
S723/HR1458 - Access to Prescription Digital Therapeutics Act HR8816 - American Medical Innovation and Investment Act of 2024 PBM Transparency and Reform S1542/HR6283 - Delinking Revenue from Unfair Gouging (DRUG) Act HR2880 - Protecting Patients Against PBM Abuses Act HR5378 - Lower Costs More Transparency Act 340B Reform HR8574 - 340B Affording Care for Communities and Ensuring a Strong Safety-net (ACCESS) Act
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS)
PBM Transparency and Reform: S1375/HR830 - Help Ensure Lower Patient (HELP) Copays Act S1542/HR6283 - Delinking Revenue from Unfair Gouging (DRUG) Act S2973 - Modernizing and Ensuring PBM Accountability Act S3430 - Better Mental Health Care, Lower Cost Drugs, and Extenders Act HR2880 - Protecting Patients Against PBM Abuses Act HR5378 - Lower Costs More Transparency Act 340B Reform HR8574 - 340B Affording Care for Communities and Ensuring a Strong Safety-net Act HR8816 - American Medical Innovation and Investment Act of 2024
International Supply Chain HR4307/S2115 - Medical Supply Chain Resiliency Act
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR), White House Office
TRIPS Waiver General IP Issues Bayh-Dole March-In Rights
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), Office of the Vice President of the United States, SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
NAFTA/USMCA Foreign Market Access issues (including IPR) International Supply Chain/Buy America - harmonize international drug manufacturing standards. Global Access to Medicines
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), Office of the Vice President of the United States, SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
TRIPS Waiver
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), Office of the Vice President of the United States, SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office